InflaRx NV (InflaRx NV) FCF Margin % : -594,850.00% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. InflaRx NV's Free Cash Flow for the three months ended in Dec. 2023 was $-11.90 Mil. InflaRx NV's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, InflaRx NV's FCF Margin % for the quarter that ended in Dec. 2023 was -594,850.00%.

As of today, InflaRx NV's current FCF Yield % is -57.90%.

The historical rank and industry rank for InflaRx NV's FCF Margin % or its related term are showing as below:

IFRX' s FCF Margin % Range Over the Past 10 Years
Min: -61061.19 Med: -59889.86 Max: -59889.86
Current: -61061.19

During the past 9 years, the highest FCF Margin % of InflaRx NV was -59889.86%. The lowest was -61061.19%. And the median was -59889.86%.

IFRX's FCF Margin % is ranked worse than
97.21% of 1041 companies
in the Biotechnology industry
Industry Median: -143.92 vs IFRX: -61061.19

InflaRx NV FCF Margin % Historical Data

The historical data trend for InflaRx NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV FCF Margin % Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-59,889.86

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-8,656.92	-594,850.00

Competitive Comparison of InflaRx NV's FCF Margin %

For the Biotechnology subindustry, InflaRx NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where InflaRx NV's FCF Margin % falls into.

InflaRx NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

InflaRx NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-41.324	/	0.069
	=	-59,889.86 %

InflaRx NV's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-11.897	/	0.002
	=	-594,850.00 %

InflaRx NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of InflaRx NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.